scispace - formally typeset
Open AccessJournal ArticleDOI

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

Reads0
Chats0
TLDR
In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.
About
This article is published in Cell.The article was published on 2021-04-29 and is currently open access. It has received 1109 citations till now. The article focuses on the topics: Vaccination & Humoral immunity.

read more

Citations
More filters
Journal ArticleDOI

Comparison of Imaging Severity Between Vaccinated and Unvaccinated COVID-19 Patients: Perspective of an Indian District

TL;DR: In this paper , the effect of vaccination status on imaging severity in patients with positive COVID-19 reverse transcription-polymerase chain reaction (RT-PCR)/antigen tests was assessed.
Journal ArticleDOI

The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines

TL;DR: In this paper , the effects of mutations on virus infectivity and neutralization resistance to convalescent and inactivated virus vaccine sera were studied and it was shown that the B.617.1.1 (Kappa) variant exhibited both higher infectivity in sera at 1 or 3 months after vaccination of 28 individuals and at 14 and 200 days after discharge of 15 convalescents.
Posted ContentDOI

Effect of prophylactic use of intra-nasal oil formulations in the hamster model of Covid-19

TL;DR: In this article, the authors reported the prophylactic application of two intra-nasal formulations provided by the National Medicinal Plant Board (NMPB), Anu oil and Til tailya in SARS-CoV2 infection hamster model.
Journal ArticleDOI

Vascular Endothelial Growth Factor Receptor, fms-Like Tyrosine Kinase-1 (Flt-1), as a Novel Binding Partner for SARS-CoV-2 Spike Receptor-Binding Domain

TL;DR: The Flt-1 receptor is a novel binding partner for SARS-CoV-2 spike RBD, and polyclonal or monoclonal anti-spike RBD antibodies can recognize either rsFlt-1 or rspike-RBD, showing cross-reactivity for the two proteins in a dose-dependent binding response.
References
More filters
Journal ArticleDOI

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

TL;DR: Infection with betacoronaviruses induces multi-specific and long-lasting T cell immunity against the structural N protein, and SARS-CoV-2-reactive T cells were found in individuals who had recovered from SARS or COVID-19 and in unexposed donors, although with different patterns of immunoreactivity.
Related Papers (5)